凯莱英(002821.SZ)拟向高瓴资本定增募资不逾23.11亿人币
凯莱英(002821.SZ)公布,公司拟以每股123.56元人民币(下同),向高瓴资本管理有限公司非公开发行股票,募资总额不超过23.11亿元,扣除发行费用後将全额用於补充公司流动资金。公司将进一步加大研发投入力度,包括连续性反应技术、生物转化技术、高端制剂技术开发、光化学、电化学等领域的前沿技术,保持公司在行业内的技术领先地位。
公司同日公布,监於目前国家政策及资本市场环境变化,并综合考虑公司实际情况、发展规划等诸多因素,公司决定终止2019年非公开发行股票事项,并向中证监申请撤回2019年非公开发行股票申请文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.